closing of a RMB 200 million Series B+ financing round. The funding was led by Qiming Venture Partners, with participation from BioVenture, C&D Emerging Industry Investment, and existing shareholder Sino-Ocean Capital.

CEC Capital Group acted as the exclusive financial advisor for Haosi Biology in this transaction.

The proceeds from this round of financing will be used to advance clinical trials and regulatory applications for the company's testing products, as well as for the research and development of mass spectrometry instrument hardware. Additionally, the funds will be utilized to expand clinical market promotion, expanding research and development, product development, and market expansion.